Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-02-27 10:11 CET (UTC+1h)
 

Justification for the lack of incurred sample reanalysis [Regulatives / Guidelines]

posted by irene - Greece, 2017-02-13 07:58  - Posting: # 17053
Views: 469

Hello,

in the EMA's "Questions & Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP)" it states the lack of incurred sample reanalysis data for a bioequivalence study can be justified. One of the points that should be adreessed is
I would like to ask if someone has ever provided these data and how the probability of a false positive outcome can be calculated. I was thinking of using simulations but it is not clear which parameters should I vary and which distributions to use (i.e. mean and sd).

Thank you in advance,

Irene

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
16,618 Posts in 3,572 Threads, 1,006 registered users;
17 users online (1 registered, 16 guests).

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed